CrossMab Products

• Recombinant Anti-TNFRSF8 × Anti-ERBB2 Bispecific Antibody (CrossMab) (BSAB-LC004)
• • Targets: CD30 & ErbB2
  • Type: CrossMab
  • Application: ELISA
  Compare

• Recombinant Anti-ADCYAP1R1 × Anti-CRCP Bispecific Antibody (CrossMab) (BSAB-LC003)
• • Targets: PAC1 receptor & CGRP receptor
  • Type: CrossMab
  • Application: ELISA
  Compare

• Recombinant Anti-ROR1 × Anti-CD3 Bispecific Antibody (CrossMab) (BSAB-LC002)
• • Targets: ROR1 & CD3
  • Type: CrossMab
  • Application: FC
  Compare

• Recombinant Anti-CSPG4 × Anti-CD3 Bispecific Antibody (CrossMab) (BSAB-LC001)
• • Targets: MCSP & CD3
  • Type: CrossMab
  • Application: FC, ELISA
  Compare

• Recombinant Anti-EGFR× Anti-Fcgr1 Bi-specific T-cell engagers (CrossMab) (BSAB-L022)
• • Targets: EGFR & Fcgr1
  • Type: CrossMab
  Compare

• Recombinant Anti-CEA× Anti-HSG Bi-specific T-cell engagers (CrossMab) (BSAB-L018)
• • Targets: CEA & HSG
  • Type: CrossMab
  Compare

• Recombinant Anti-Ang2× Anti-VEGFA Bi-specific T-cell engagers (CrossMab) (BSAB-L017)
• • Targets: Ang2 & VEGFA
  • Type: CrossMab
  Compare

• Recombinant Anti-HRPO × Anti-biotin Bispecific Antibody (CrossMab) (CROSS-L045)
• • Targets: HRPO & biotin
  • Type: CrossMab
  • Application: FuncS, Immunoassay
  Compare

• Recombinant Anti-EGFR × Anti-doxorubicin Bispecific Antibody (CrossMab) (CROSS-L044)
• • Targets: EGFR & doxorubicin
  • Type: CrossMab
  • Application: FuncS, Pretargeting system for therapic agent delivery
  Compare

• Recombinant Anti-Tweak × Anti-IL17 Bispecific Antibody (CrossMab) (CROSS-L043)
• • Targets: Tweak & IL17
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-PLAP × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L042)
• • Targets: PLAP & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CR1/2 × Anti-ΦX174 Bispecific Antibody (CrossMab) (CROSS-L041)
• • Targets: CR1/2 & ΦX174
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-VEGFA × Anti-VEGFA Bispecific Antibody (CrossMab) (CROSS-L040)
• • Targets: VEGFA & VEGFA
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-Kit × Anti-VCAM-1 Bispecific Antibody (CrossMab) (CROSS-L039)
• • Targets: Kit & VCAM-1
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-Fibrin × Anti-PLAU Bispecific Antibody (CrossMab) (CROSS-L038)
• • Targets: Fibrin & PLAU
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-TFRC × Anti-gp40 Bispecific Antibody (CrossMab) (CROSS-L037)
• • Targets: TFRC & gp40
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-PLAT × Anti-Fibrin Bispecific Antibody (CrossMab) (CROSS-L036)
• • Targets: PLAT & Fibrin
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-FcγRI × Anti-EGF Bispecific Antibody (CrossMab) (CROSS-L035)
• • Targets: FcγRI & EGF
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-S. pneumoniae × Anti-FcαR Bispecific Antibody (CrossMab) (CROSS-L034)
• • Targets: S. pneumoniae & FcαR
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CC531 × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L033)
• • Targets: CC531 & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CC531 × Anti-CD8 Bispecific Antibody (CrossMab) (CROSS-L032)
• • Targets: CC531 & CD8
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD59 × Anti-CD38 Bispecific Antibody (CrossMab) (CROSS-L031)
• • Targets: CD59 & CD38
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-FcγRI × Anti-CD33 Bispecific Antibody (CrossMab) (CROSS-L030)
• • Targets: FcγRI & CD33
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-SLA × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L029)
• • Targets: SLA & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-IL2RA × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L028)
• • Targets: IL2RA & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-HN × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L027)
• • Targets: HN & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L026)
• • Targets: HER2 & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD20 × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L025)
• • Targets: CD20 & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD19 × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L024)
• • Targets: CD19 & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD20 × Anti-CD22 Bispecific Antibody (CrossMab) (CROSS-L023)
• • Targets: CD20 & CD22
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD59 × Anti-CD19 Bispecific Antibody (CrossMab) (CROSS-L022)
• • Targets: CD59 & CD19
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CGA × Anti-CGB Bispecific Antibody (CrossMab) (CROSS-L021)
• • Targets: CGA & CGB
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-VEGFR2 × Anti-VEGFR2 Bispecific Antibody (CrossMab) (CROSS-L020)
• • Targets: VEGFR2 & VEGFR2
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-HLA-A × Anti-CD55 Bispecific Antibody (CrossMab) (CROSS-L019)
• • Targets: HLA-A & CD55
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-G250 × Anti-CD55 Bispecific Antibody (CrossMab) (CROSS-L018)
• • Targets: G250 & CD55
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-IL17 × Anti-TNF Bispecific Antibody (CrossMab) (CROSS-L017)
• • Targets: IL17 & TNF
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-BCMA × Anti-TACI Bispecific Antibody (CrossMab) (CROSS-L016)
• • Targets: BCMA & TACI
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD8 × Anti-IL2 Bispecific Antibody (CrossMab) (CROSS-L015)
• • Targets: CD8 & IL2
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD4 × Anti-IL2 Bispecific Antibody (CrossMab) (CROSS-L014)
• • Targets: CD4 & IL2
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-EGFR × Anti-HER3 Bispecific Antibody (CrossMab) (CROSS-L013)
• • Targets: EGFR & HER3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-HER2 × Anti-HER2 Bispecific Antibody (CrossMab) (CROSS-L012)
• • Targets: HER2 & HER2
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-FIXa × Anti-FX Bispecific Antibody (CrossMab) (CROSS-L011)
• • Targets: FIXa & FX
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-FcγRI × Anti-DENV Bispecific Antibody (CrossMab) (CROSS-L010)
• • Targets: FcγRI & DENV
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD33 × Anti-DENV Bispecific Antibody (CrossMab) (CROSS-L009)
• • Targets: CD33 & DENV
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CD15 × Anti-DENV Bispecific Antibody (CrossMab) (CROSS-L008)
• • Targets: CD15 & DENV
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-GLUT2 × Anti-CTLA-4 Bispecific Antibody (CrossMab) (CROSS-L007)
• • Targets: GLUT2 & CTLA-4
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-FcγRIII × Anti-CD30 Bispecific Antibody (CrossMab) (CROSS-L006)
• • Targets: FcγRIII & CD30
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-MET × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L005)
• • Targets: MET & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CXCR5 × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L004)
• • Targets: CXCR5 & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-Ovarian cancer × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L003)
• • Targets: Ovarian cancer & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-CLEC12A × Anti-CD3 Bispecific Antibody (CrossMab) (CROSS-L002)
• • Targets: CLEC12A & CD3
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare

• Recombinant Anti-EGFR × Anti-FcγRIII Bispecific Antibody (CrossMab) (CROSS-L001)
• • Targets: EGFR & FcγRIII
  • Type: CrossMab
  • Application: FuncS, Promising therapeutic agent
  Compare